Clove Oil

What it is

Clove oil is produced by steam distillation of dried buds from the clove tree (Syzygium aromaticum / Eugenia caryophyllus), native to the Maluku Islands (Indonesia). Cloves were one of the reasons for the Age of Discovery: Venetian merchants maintained a trade monopoly over them, and Magellan sent the expedition that became the first circumnavigation of the globe specifically in their pursuit.

Clove oil has been used in dentistry for at least 2,500 years. Hippocrates mentioned it as a remedy for toothache; in medieval Europe cloves were chewed for anaesthesia during tooth extractions. In modern dentistry, ZOE cement (zinc oxide + eugenol) is an ADA-approved standard for temporary fillings and pulpitis treatment.

The main component (70–90%) is eugenol (4-allyl-2-methoxyphenol). Secondary components include eugenyl acetate, β-caryophyllene and vanillin.

How it works

Sodium channel blockade (anaesthesia). Eugenol binds to voltage-gated sodium channels (Nav1.7, Nav1.8) of pain-sensing neurons, reducing the rate of depolarisation. Tanaka et al. (1998) showed the mechanism is analogous to lidocaine but reversible on washout. The effect onset is 2–4 minutes of contact.

Antiseptic action. Eugenol disrupts bacterial cell membrane structure — the mechanism is analogous to other terpenoid phenols (thymol, carvacrol). Active against S.mutans, S.sobrinus, P.gingivalis, A.actinomycetemcomitans and Candida yeasts. Cai & Wu (1996) demonstrated MIC 0.1–0.4 mg/mL against the main cariogenic and periodontal pathogens.

Anti-inflammatory component. β-caryophyllene (3–12% of the oil) is a CB2 receptor agonist of the endocannabinoid system, reducing the inflammatory response through a neuroimmune pathway without psychoactive effect. This explains the soothing action of clove on inflamed gums.

Antioxidant effect. Eugenol is an effective free radical scavenger (DPPH IC₅₀ approximately 22 μM), comparable to BHT.

Efficacy

Kaur et al. (2014) showed that clove oil at 1% produced inhibition zones for S.mutans and L.acidophilus comparable to 0.2% chlorhexidine in an agar diffusion test. The combination of antiseptic and anaesthetic effects in a single ingredient has no analogue among natural components.

In clinical use, ZOE materials (containing 10–40% eugenol) demonstrate effectiveness in temporary fillings for 3–6 months — evidence of sustained activity in a closed system.

Safety

The concentration threshold is the critical parameter. ≤1% in mouthwashes and toothpastes: safe, without irritation. 1–2%: mild burning sensation possible in sensitive patients. >2%: risk of chemical mucosal burn (demonstrated in vitro by Prashar et al. 2006 on epithelial cells).

The FDA recognises eugenol as Category I (Generally Recognized As Safe and Effective) as a local oral analgesic at concentrations 0.05–1.5%. EU SCCS has confirmed safety in cosmetic products at concentrations ≤0.5%.

Approximately 1% of the population has eugenol allergy (cross-reaction with cinnamaldehyde and spice allergens). In the presence of allergy — absolute contraindication.

Role in the QDRO formula

Clove oil is the "fast-acting" antiseptic and analgesic in the v.pro line. A working concentration of 0.5% provides a noticeable analgesic effect for gum hypersensitivity without irritation. Paired with myrrh it creates a broad-spectrum antiseptic base. The warm spicy aroma fits organically into the "clinical-pharmaceutical" olfactory profile of v.pro. Requires declaration on EU packaging as an allergen (Regulation EC 1223/2009).